224 related articles for article (PubMed ID: 24913706)
41. Promoter hypermethylation of RAR-β tumor suppressor gene in gastric carcinoma: Association with histological type and clinical outcomes.
Mohsenzadeh M; Sadeghi RN; Vahedi M; Kamani F; Hashemi M; Asadzadeh H; Zali MR
Cancer Biomark; 2017 Jul; 20(1):7-15. PubMed ID: 28759951
[TBL] [Abstract][Full Text] [Related]
42. Lack of Correlation between Aberrant p16, RAR-β2, TIMP3, ERCC1, and BRCA1 Protein Expression and Promoter Methylation in Squamous Cell Carcinoma Accompanying Candida albicans-Induced Inflammation.
Terayama Y; Matsuura T; Ozaki K
PLoS One; 2016; 11(7):e0159090. PubMed ID: 27410681
[TBL] [Abstract][Full Text] [Related]
43. RAR beta2 suppression in head and neck squamous cell carcinoma correlates with site, histology and age.
Olasz J; Juhász A; Remenár E; Engi H; Bak M; Csuka O; Kásler M
Oncol Rep; 2007 Jul; 18(1):105-12. PubMed ID: 17549354
[TBL] [Abstract][Full Text] [Related]
44. PTEN and p16 genes as epigenetic biomarkers in oral squamous cell carcinoma (OSCC): a study on south Indian population.
Sushma PS; Jamil K; Kumar PU; Satyanarayana U; Ramakrishna M; Triveni B
Tumour Biol; 2016 Jun; 37(6):7625-32. PubMed ID: 26687648
[TBL] [Abstract][Full Text] [Related]
45. Methylation in the p53 promoter in epithelial ovarian cancer.
Chmelarova M; Krepinska E; Spacek J; Laco J; Beranek M; Palicka V
Clin Transl Oncol; 2013 Feb; 15(2):160-3. PubMed ID: 22855178
[TBL] [Abstract][Full Text] [Related]
46. Aberrant promoter hypermethylation of p16 and MGMT genes in oral squamous cell carcinomas and the surrounding normal mucosa.
Kato K; Hara A; Kuno T; Mori H; Yamashita T; Toida M; Shibata T
J Cancer Res Clin Oncol; 2006 Nov; 132(11):735-43. PubMed ID: 16791592
[TBL] [Abstract][Full Text] [Related]
47. p16 gene alterations in human ovarian cancers: comparison between tissue and blood samples.
Bammidi LS; Neerukonda GN; Murthy S; Kanapuram RD
Int J Gynecol Cancer; 2012 May; 22(4):553-60. PubMed ID: 22344043
[TBL] [Abstract][Full Text] [Related]
48. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
49. DNA hypermethylation and clinicopathological features in breast cancer: the Western New York Exposures and Breast Cancer (WEB) Study.
Tao MH; Shields PG; Nie J; Millen A; Ambrosone CB; Edge SB; Krishnan SS; Marian C; Xie B; Winston J; Vito D; Trevisan M; Freudenheim JL
Breast Cancer Res Treat; 2009 Apr; 114(3):559-68. PubMed ID: 18463976
[TBL] [Abstract][Full Text] [Related]
50. [Expression and promotor methylation of p73 gene in ovarian epithelial tumors].
Zhang YL; Guo XR; Shen DH; Cheng YX; Liang XD; Chen YX; Wang Y
Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):33-8. PubMed ID: 22455848
[TBL] [Abstract][Full Text] [Related]
51. Aberrant gene promoter methylation of E-cadherin, p16
Burassakarn A; Pientong C; Sunthamala N; Chuerduangphui J; Vatanasapt P; Patarapadungkit N; Kongyingyoes B; Ekalaksananan T
Med Oncol; 2017 Jul; 34(7):128. PubMed ID: 28573642
[TBL] [Abstract][Full Text] [Related]
52. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
53. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer.
Tian H; Yan L; Xiao-Fei L; Hai-Yan S; Juan C; Shan K
Clin Epigenetics; 2019 Oct; 11(1):153. PubMed ID: 31666131
[TBL] [Abstract][Full Text] [Related]
54. Epigenetic and genetic alterations in duodenal carcinomas are distinct from biliary and ampullary carcinomas.
Kim SG; Chan AO; Wu TT; Issa JP; Hamilton SR; Rashid A
Gastroenterology; 2003 May; 124(5):1300-10. PubMed ID: 12730870
[TBL] [Abstract][Full Text] [Related]
55. FBXW7 is involved in the acquisition of the malignant phenotype in epithelial ovarian tumors.
Kitade S; Onoyama I; Kobayashi H; Yagi H; Yoshida S; Kato M; Tsunematsu R; Asanoma K; Sonoda K; Wake N; Hata K; Nakayama KI; Kato K
Cancer Sci; 2016 Oct; 107(10):1399-1405. PubMed ID: 27486687
[TBL] [Abstract][Full Text] [Related]
56. [Disfigurement of p16INK4A gene expression in development of ovarian cancer and the mechanism].
Li M; Huang ZJ; Dong WH; Li XY; Wang XY; He XH; Wang H; Wang ZH
Zhonghua Fu Chan Ke Za Zhi; 2006 Jun; 41(6):408-12. PubMed ID: 16831366
[TBL] [Abstract][Full Text] [Related]
57. Aberrant promoter methylation of p16(INK4a), RARB2 and SEMA3B in bronchial aspirates from patients with suspected lung cancer.
Grote HJ; Schmiemann V; Geddert H; Rohr UP; Kappes R; Gabbert HE; Böcking A
Int J Cancer; 2005 Sep; 116(5):720-5. PubMed ID: 15849750
[TBL] [Abstract][Full Text] [Related]
58. [Clinical significance of detection of tumor suppressor genes aberrant methylation in cervical carcinoma tissue].
Xu J; Wang HL; Lu GC; Wang ZJ; Lin X; Zhou HW
Zhonghua Fu Chan Ke Za Zhi; 2007 Jun; 42(6):394-7. PubMed ID: 17697601
[TBL] [Abstract][Full Text] [Related]
59. Promoter hypermethylation of p16 and APC in gastrointestinal cancer patients.
Erdem B; Küçükyıldırım S; Sağlar E; Polat Z; Mergen H
Turk J Gastroenterol; 2014 Oct; 25(5):512-7. PubMed ID: 25417611
[TBL] [Abstract][Full Text] [Related]
60. IGF-II promoter specific methylation and expression in epithelial ovarian cancer and their associations with disease characteristics.
Qian B; Katsaros D; Lu L; Canuto EM; Benedetto C; Beeghly-Fadiel A; Yu H
Oncol Rep; 2011 Jan; 25(1):203-13. PubMed ID: 21109978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
